AOD-9604 (5 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously, typically in the morning on an empty stomach. Rotate injection sites (abdomen, thighs, upper arms) to minimize local irritation.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 1.667 mg/mL, 1 unit = 0.01 mL » 16.67 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; stable for 1+ year.
• Reconstituted: refrigerate at 2 to 8 °C; use within 3 to 4 weeks; avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 12 week daily protocol with gradual titration.

Peptide Vials (AOD-9604, 5 mg each):

• 8 weeks: ~5 vials. 12 weeks: ~8 vials. 16 weeks: ~11 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (5 vials): 2 bottles. 12 weeks (8 vials): 3 bottles. 16 weeks (11 vials): 4 bottles.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes (U-100, 29 to 31 gauge); dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent

lipohypertrophy.

• Inject slowly; wait a few seconds before withdrawing the needle.
• Each 5 mg vial provides approximately 10 days of dosing at 500 mcg/day or 16 to 17 days at 300

mcg/day.

How This Works

AOD-9604 is a modified C-terminal fragment of human growth hormone that retains the lipolytic (fat-reducing) domain without the growth-promoting effects. It binds to adipose tissue and triggers breakdown of stored fat while blocking new fat storage (re-esterification) in adipocytes. At the molecular level, chronic AOD-9604 administration upregulates b3-adrenergic receptors in fat tissue, reversing obesity-related suppression of these fat-burning receptors. Unlike full-length hGH, AOD-9604 does not meaningfully elevate IGF-1 levels or worsen glucose tolerance, making its tolerability indistinguishable from placebo in human trials.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Supports reductions in fat mass and increases in fat oxidation over time; clinical trials showed modest but

statistically significant weight loss (approximately 2.6 kg vs. 0.8 kg placebo over 12 weeks at 1 mg/day).

• Preferential loss of abdominal fat observed, resembling the pattern seen with low-dose hGH therapy.
• Does not meaningfully raise IGF-1 and shows a placebo-like safety profile in human studies; no

anti-AOD9604 antibodies detected.

• Emerging regenerative potential: preclinical studies suggest possible cartilage repair and bone health

benefits.

• Generally well tolerated; occasional mild injection-site reactions (redness, itch) may occur with

subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a hypocaloric, protein-forward diet tailored to energy needs; AOD-9604 is best viewed as a

supportive aid to fat loss rather than a stand-alone solution.

• Combine resistance training and aerobic activity to reinforce metabolic adaptations.
• Prioritize sleep and stress management to support adherence and recovery.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Safety and metabolism of AOD9604 as a nutraceutical ingredient (J Endocrinol Metab, 2014).
2. Safety and tolerability of AOD9604 in humans; placebo-like safety profile (J Endocrinol Metab, 2013).
3. Effects of hGH and AOD9604 on lipid metabolism in obese mice (Endocrinology / OUP).
4. Drug treatment of the overweight patient; AOD-9604 RCT summary (Gastroenterology).